Sareum Share Price. SAR - Stock Quote, Charts, Trade History, Share Chat, Financials. Sareum Holdings Plc

Gold vs US Dollar

Home
Investing
Stocks
UK
LSE
Sareum Holdings Plc (SAR)
Sareum Holdings Plc (SAR) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Sareum Holdings Plc	LSE:SAR	London	Ordinary Share	GB00BMC3RJ87	ORD GBP 0.0125

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	135.00	13,491	07:45:39

Bid Price		Offer Price	High Price	Low Price	Open Price
130.00		140.00	135.00	135.00	135.00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceutical Preparations	0.00	-2.17	-	-	91.89

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
16:19:00	O	73	135.80	GBX

Related Shares
Astrazeneca (AZN), Gsk (GSK), Yourgene Health (YGEN), Fusion Antibodies (FAB)

Sareum (SAR) Latest News

Sareum News

Date	Time	Source	Headline
06/6/2023	13:36	ALNC	IN BRIEF: Sareum doses first subjects in psoriasis drug trial
06/6/2023	07:00	UKREG	Sareum Holdings PLC Dosing commences in Phase 1a trial of SDC-801
18/5/2023	14:31	ALNC	TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect
18/5/2023	07:00	UKREG	Sareum Holdings PLC Phase 1a clinical trial for SDC-1801
05/5/2023	11:26	ALNC	Sareum receives Australian approval for psoriasis drug clinical trial
05/5/2023	11:11	ALNC	AIM WINNERS & LOSERS: Aptamer says struggling to convert pipeline
05/5/2023	09:20	UKREG	Sareum Holdings PLC Approval to initiate Phase 1 clinical trial
22/3/2023	11:47	ALNC	Sareum Holdings interim loss widens as touts psoriasis candidate drug
22/3/2023	07:00	UKREG	Sareum Holdings PLC Half-Year Report
17/3/2023	18:06	ALNC	IN BRIEF: Sareum makes trial application for SDC-1801 in Australia

More Sareum News

Sareum Investors Sareum Takeover Rumours

Sareum (SAR) Discussions and Chat

Sareum Forums and Chat

Date	Time	Title	Posts
09/6/2023	22:22	Sareum 2015	14,058
28/11/2022	20:37	SRA737	16
05/8/2021	08:49	No more rns until current project closed	-
04/7/2021	20:52	SAR 2013 , SHORT THE ARSE OUT OF IT THREAD	326
08/1/2021	18:09	SAR - Sareum Holdings drug discovery	370

Add a New Thread

Sareum (SAR) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2023-06-09 15:19:00	135.80	73	99.13	O
2023-06-09 14:37:18	130.00	526	683.80	O
2023-06-09 14:22:20	133.50	2,000	2,670.00	O
2023-06-09 14:14:44	134.50	2,029	2,729.01	O
2023-06-09 14:07:23	133.50	225	300.38	O

View all Sareum trades in real-time

Sareum (SAR) Top Chat Posts

Top Posts
Posted at 06/5/2023 15:46 by peaceandlove An absolute brilliant day for Sareum yesterday. A long way to go, but let's give credit where credits due - the switch to Australia has proved to be very shrewd. I noticed a few moaning at the stock price. Why? 48% up YTD I feel in this current economic climate is actually very impressive. Personally I don't care - I've a decent holding and will hold until it's over. The share price will take care of itself as we move forward. Can't wait to hear how 737 is progressing. Good Luck! Read Full Thread Follow Reply
Posted at 30/4/2023 19:49 by criticalthinker1 AIM INVESTMENT Risk and reward can be a two way street....add a sprinkle of wealth management and an element of risk mitigation can be exercised. Just my thoughts re comments on LSE re HBDs noteable find and some valuations. As I'm sure everyone is aware shares held for 2 years or longer on AIM are void of IHT. I'm sure many appreciate given house values many are liable to 40 percent tax after £325k if single or £650k if a couple. The first HNWI invested £900k at 2.8p (£1.40) on the 1st June 2021, nearly 2 years, and of which anything above 84p would see their estate do a fingers up to the treasury on any/if any gains. So far so good. The same individual on 15th June 2021 added £1.47m at 4.9p (£2.45) which would see them do a similar hand gesture at £1.47. The subscription on 9th August 2021 at 8.25p (£4.12) would require a share price of £2.47 before said hand gesture could be repeated. We were nearly at this share price before the 'debacle' and imo overly negative market response. The subscriptions were for both the progress of 1801 (of which 1802 benefits) and ongoing operational expenses. Of which the latter I firmly believe following the last meeting includes translational studies of 1802. This also was before the 737 'debacle', which again imo is a further to be feather in our cap. AIM is definitely high risk. But from experience a little check list helps see the wood for the trees re a 'safer' AIM investment. Check out those on the payroll and prior/ongoing positions. That's a heads up for me when looking at investing...also if they hold and add (when able...) is another indicator. Regards Steadydanny Read Full Thread Follow Reply
Posted at 15/3/2023 13:37 by criticalthinker1 I have read the Edison report and note they advise funding to commence is in place but more will be needed to complete. Be interesting to see if our HNWIs are going to pop their hand in their pocket. HNWI #1 Subscibed £900k at 2.8p (£1.40) and then the same person subscribed £1.47m at 4.9p (£2.45). They then took advantage of the first set of warrants and added £180k. I note their second subscription had a 1:3 warrant available if the share price held above £3.50 (7p old money) for 5 days or more. Which it did. I believe they could add another £490k if they exercised those warrants to further progress 1801. That would be a vote of confidence, but why would they not just hold onto those golden warrants and undertake a new subscription at the present share price? It's also worth noting the second HNWI subscribed £1m at 7p (£3.50) with warrants if greater than 9p (£4.50) for 5 days. This was not on a whim as i believe the penultimate subscription was a joint venture between multiple HNWIS of a £1m subscription at 8.25p (£4.12) with warrants at 10.25p (£5.12). Also a further £1.63m was raised by new and existing HNWIS at 5p (£2.50).... I suspect they are going to add more via a subscription to show confidence in their investments. Interesting times with the BOD possibly in discussions with HNWI #1 and the others. All just IMO. Read Full Thread Follow Reply
Posted at 02/3/2023 14:20 by horridhenry thanks to Lutonnews on LSE - "As far as negative posters go I agree there is a place on the bb for every opinion. My only gripe with some is that it's not what they say but the way that they say it. Sometimes it been difficult to separate the genuine negative view on here from that of the serial mischief maker. It's certainly frustrating to see yet again the weeks trickle by without a timely update. But most lths are aware that the current share price is irrelevant in the whole scheme of things as a positive update will result in the share price rising immediately to a much higher level. As always plenty of promise from behind the scenes, whether that promise will turn into something concrete is the gamble everyone who is invested here must be prepared to take. ATB." The ones left posting are losers with giant chips on their shoulders who will never convince long term holders that they are anything other than pillocks. Some of them live in Scotland too - inevitable - the one on here is Isla Bryson or Nicola Sturgeon, or with it's little friend both - both on ignore but uncanny how often they turn up together Read Full Thread Follow Reply
Posted at 20/2/2023 18:35 by criticalthinker1 Sareum notes the US FDA approval of Sotyktu™ (deucravacitinib), for Moderate-to-Severe Plaque Psoriasis, the first TYK2 inhibitor to gain FDA approval Cambridge, UK, 12 September 2022 – Sareum Holdings plc (AIM: SAR), a clinical stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, notes the announcement from Bristol Myers Squibb (BMS) that the US Food and Drug Administration (FDA) has approved Sotyktu™(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This announcement supports Sareum’s confidence in its broader portfolio of TYK2/JAK1 inhibitors focused on autoimmune disease. This is the first approval by the FDA of a medicine based on TYK2, a member of the JAK cell signalling family. We believe it provides clinical validation for this class of therapeutic, and for the broader TYK2/JAK1 signalling family, which underpins Sareum’s clinical portfolio. The Company believes the TYK2/JAK1 signalling pathway which it is pursuing offers potential for superior efficacy compared with agents, such as deucravacitinib, which block just one of the two kinases. The Sotyktu approval is based on a pivotal Phase 3 study of deucravacitinib which demonstrated superior efficacy against placebo and [standard of care] Otezla. It is also encouraging to note that deucravacitinib was well tolerated in the Phase 3 study. Unlike some other medicines in the JAK inhibitor class, the FDA is not requiring boxed warnings for deucravacitinib around the heightened risk of serious heart-related events. “We’re encouraged that the FDA has approved Sotyktu (deucravacitinib),” said Tim Mitchell, CEO of Sareum. “We believe this validates the potential of this new therapeutic class and supports our own growing confidence around our lead programme and our broader portfolio of TYK2/JAK1 inhibitors “TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis. Sareum has submitted a Clinical Trial Authorisation (CTA) to the UK’s Medicines and Healthcare Products Regulatory Agency to initiate a clinical trial of SDC-1801, with an initial focus on psoriasis, and hopes to begin dosing patients in 2023, subject to regulatory approvals.” Sareum will update on the regulatory progress of SDC-1801 in due course. Bristol Myers Squibb’s announcement can be found here. The stars are aligning. Read Full Thread Follow Reply
Posted at 08/2/2023 17:55 by criticalthinker1 BIA website. Sareum Ltd Sareum develops next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, which, subject to MHRA approval, will shortly enter clinical development with an initial focus on psoriasis. Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials. Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Sareum is based in Cambridge, UK, and it’s parent company, Sareum Holdings plc, is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. ADD TO MY FAVOURITES Details Small-medium corporate Drug Discovery hxxp://www.sareum.com/ SCROLL UP BIA, LABS, Victoria House, Bloomsbury Way, London, WC1B 4DA info@bioindustry.org +44 (0)20 7630 2180 So BIA say we will shortly enter CTA. Funny how this was not available before our CTA pass off amd we have as a Company said nothing to our shareholders. I'm not happy about this! Read Full Thread Follow Reply
Posted at 29/1/2023 19:57 by criticalthinker1 In respect of SOGs post on LSE. MARCH 2021. SAREUM POSTS Sareum Notes SRA737 Combination Data to be Presented at the AACR Annual Meeting Cambridge, UK, 25 March 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, notes that researchers from the Institute of Cancer Research (ICR) will present preclinical data on the combination of the Chk1 inhibitor SRA737 with AstraZeneca’s WEE1 inhibitor, adavosertib, at the forthcoming American Association for Cancer Research (AACR) Annual Meeting. SRA737 was discovered and initially developed by scientists at The ICR in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a c.$300 million plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement. The poster* describes how the combination of SRA737 and adavosertib potentiated cell death in cellular models of ovarian, breast and pancreatic cancer and in disease model studies of ovarian and breast cancer. * “A study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell lines” (Abstract 1010), to be presented on-line during the “Cellular Responses to Anticancer Drugs” session on 10 April 2021. hxxps://www.abstractsonline.com/pp8/#!/9325/presentation/2082 Sareum’s CSO, Dr John Reader, commented: “We are encouraged to see yet another potential treatment modality for SRA737, in this case in tumours with a TP53 mutation, a mutation that is present in approximately half of all solid tumour cancers.” I can see why we have been approached re 737 handback. And also looking forward to seeing 1801 get approved for forward progression (here or abroad)even if MHRA are a a shill. I suspect GSK are watching Sareum with great interest. Read Full Thread Follow Reply
Posted at 23/12/2022 18:32 by lovepeaceharmony As the sareum share price has been utterly decimated on 2022...let's look to next year with renewed positivity and optimism in our hearts for sareum...as afham on lse might observe....we are going to clinic.. Sareum healing the world...many Happy returns chaps 2023...the year of the rerate... 2024...potentially the year of the rerate 2025... maybe the year of the rerate.. 2026...sareum will likely be in clinic.. 2027...worse case..sareum enters clinic 2028..OK..promise..sareum are in clinic Read Full Thread Follow Reply
Posted at 20/12/2022 17:02 by lovepeaceharmony HorrorHenry...I'm not Pete...this is the start of the share price falling again.. Lots of excitement on Lse...about 737 coming back... I suppose owning 27.5% of something that nobody wants is better than nothing.... Loving your posts... "Don't listen to this guy", you demand.. Just like an arrogant sareumite...do as I say...don't listen to opposing ideas... Heres an idea..check the share price over 2022...70% fall... Many Happy Returns Read Full Thread Follow Reply
Posted at 20/12/2022 14:09 by cerrito Belated comments on Friday’s AGM - the first of any AGM I have been to since the 2019 SAR AGM. It had the best energy of all the SAR AGM’s I went to from 2007 and 2019. The first SAR AGM I can remember going to where there was no discussion on the cash runway. I regret not pursuing this, I thought John came over very well. The next RNS will I assume be sometime in January with the news that GSK have returned to CPF the 737 license to be followed by one a few weeks later saying that CPF have received all the R&D info from GSK. A toss up is if the next RNS will be the interims due by end March or definitive news on the CTA. I am bracing myself for a few months of treading water both ref 737 and 1801;.hopefully I am wrong. In terms of the projects, I have always taken in my stride that GSK are returning 737 and for me good that they came to a quick decision and will very probably be professional in the return of the license and we have every reason to believe that the data will be delivered quote without delay unquote. I should have pressed Tim as to what exactly he is aiming to reach in the month he said it would take him to study the data especially as there is the unknown about the amount of info on the genetics. To me the main question is the decision making process at the CPF. I need to do some more research on them but I have always wondered about how commercial they are; I have in previous AGM’s sensed they have frustrated Dr Parker although in this AGM he was at pains to emphasize that the preliminary 737discussions have been constructive. Three areas of fretting by me . One is that there is the possibility of there being a genuine difference of views between the two teams as to what the data says and the commercial implications. The second is that SAR and CPF are completely different organizations as regards size, culture and philosophy. The third is that SAR no doubt places a higher premium in any license agreement on immediate cash, especially with the current share price. Hopefully I am fretting unnecessarily and good that we have Dr Parker to engage with them. I thought at the meeting I heard Dr Parker say they could buy them out, but did not hear it listening to the recording.…certainly possible but time consuming to construct a deal. With hindsight \|I should have probed more in the costs of the delay with 1801 CTA approval. I classify the costs into 3 categories. The first and easiest to quantify is the direct costs in engaging with the other Regulatory authority and if they were to approve it if the Manchester cohort could be used or another cohort in a different location organized. The second is the opportunity cost given that this is consuming so much of management’s time. Silly me for not finding out what exactly Tim and John would have been doing if they had not had to focus on this. The third is the time value of money and the general cost of the delay. I rather regret that I did not probe on where we are on 1802. I note the comment that it has not been delayed by management being involved with the CTA and also they have not started any discussions with a CRO on this. PS Granted that it was a rail strike Friday but Broadgate was deserted so am pleased I have no BLND shares at the moment and indeed Peel Hunt’s offices also appeared deserted. Read Full Thread Follow Reply

Sareum share price data is direct from the London Stock Exchange

Your Recent History

LSE

SAR

Sareum

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230610 00:54:53